Genome sequencing with comprehensive variant calling identifies structural variants and repeat expansions in a large fraction of individuals with ataxia and/or neuromuscular disorders.
ataxia
genome sequencing
neuromuscular disorders
repeat expansion
single nucleotide variant
structural variant
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
02
2023
accepted:
21
04
2023
medline:
5
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
epublish
Résumé
Neuromuscular disorders (NMDs) have a heterogeneous etiology. A genetic diagnosis is key to personalized healthcare and access to targeted treatment for the affected individuals. In this study, 861 patients with NMDs were analyzed with genome sequencing and comprehensive variant calling including single nucleotide variants, small insertions/deletions (SNVs/INDELs), and structural variants (SVs) in a panel of 895 NMD genes, as well as short tandem repeat expansions (STRs) at 28 loci. In addition, for unsolved cases with an unspecific clinical presentation, the analysis of a panel with OMIM disease genes was added. In the cohort, 27% (232/861) of the patients harbored pathogenic variants, of which STRs and SVs accounted for one-third of the patients (71/232). The variants were found in 107 different NMD genes. Furthermore, 18 pediatric patients harbored pathogenic variants in non-NMD genes. Our results highlight that for children with unspecific hypotonia, a genome-wide analysis rather than a disease-based gene panel should be considered as a diagnostic approach. More importantly, our results clearly show that it is crucial to include STR- and SV-analyses in the diagnostics of patients with neuromuscular disorders.
Identifiants
pubmed: 37273706
doi: 10.3389/fneur.2023.1170005
pmc: PMC10234573
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1170005Informations de copyright
Copyright © 2023 Ek, Nilsson, Engvall, Malmgren, Thonberg, Pettersson, Anderlid, Hammarsjö, Helgadottir, Arnardottir, Naess, Nennesmo, Paucar, Hjartarson, Press, Solders, Sejersen, Lindstrand and Kvarnung.
Déclaration de conflit d'intérêts
AL has received honoraria from Illumina Inc., and has been an advisor for Oxford Nanopore Technologies, both unrelated to the content in this article. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Orphanet J Rare Dis. 2017 Sep 6;12(1):151
pubmed: 28877744
J Med Genet. 2022 Jun;59(6):559-567
pubmed: 33820833
Genome Med. 2021 Mar 17;13(1):40
pubmed: 33726816
Neuromuscul Disord. 2021 Dec;31(12):1313-1357
pubmed: 34930546
Neurol Genet. 2018 Feb 01;4(1):e212
pubmed: 29417091
Genome Med. 2019 Nov 7;11(1):68
pubmed: 31694722
J Hum Genet. 2017 Feb;62(2):243-252
pubmed: 27708273
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Lancet Neurol. 2022 Mar;21(3):234-245
pubmed: 35182509
Genet Med. 2022 Nov;24(11):2296-2307
pubmed: 36066546
Genome Med. 2021 Aug 9;13(1):126
pubmed: 34372915
JAMA Neurol. 2015 Dec;72(12):1424-32
pubmed: 26436962
Mol Genet Genomic Med. 2020 May;8(5):e1205
pubmed: 32154989
Genet Med. 2020 Sep;22(9):1478-1488
pubmed: 32528171
Genet Med. 2021 Nov;23(11):2160-2170
pubmed: 34234304